<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384930</url>
  </required_header>
  <id_info>
    <org_study_id>9797</org_study_id>
    <secondary_id>H6D-MC-LVHG</secondary_id>
    <nct_id>NCT00384930</nct_id>
  </id_info>
  <brief_title>Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICOS Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, parallel-design, multinational,
      12-week study to compare the efficacy, dose response, and safety of tadalafil once a day
      versus placebo in men with signs and symptoms of benign prostatic hyperplasia, including
      lower urinary tract symptoms.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary Analysis</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive Analysis</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) (Irritative) Subscore</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Question 7 (Nocturia)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BII)</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Answer &quot;Yes&quot; to the Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in Peak Urinary Flow</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) EF Domain</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1058</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg tadalafil tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg tadalafil tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg tadalafil tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 mg tadalafil tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
    <other_name>IC351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>5 mg tadalafil tablet by mouth once a day for twelve weeks.</description>
    <arm_group_label>3</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
    <other_name>IC351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>10 mg tadalafil tablet by mouth once a day for twelve weeks.</description>
    <arm_group_label>4</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
    <other_name>IC351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tadalafil</intervention_name>
    <description>20 mg tadalafil tablet by mouth once a day for twelve weeks.</description>
    <arm_group_label>5</arm_group_label>
    <other_name>LY450190</other_name>
    <other_name>Cialis</other_name>
    <other_name>IC351</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo tablet taken by mouth one a day for twelve weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males, 45 years or older, with benign prostatic hyperplasia, including lower urinary
             tract symptoms for at least 6 months prior to Visit 1 and an International Prostate
             Symptom Score (IPSS) greater than or equal to 13 at Visit 2.

          -  Agree not to use approved or experimental benign prostatic hyperplasia or erectile
             dysfunction treatments anytime during the study

          -  Have not taken finasteride or dutasteride therapy, any other lower urinary tract
             symptom (LUTS) therapy or phosphodiesterase type 5 (PDE5) inhibitors for specified
             duration of time prior to Visit 2.

          -  Have a prostate specific antigen (PSA) score within acceptable range defined for study
             or negative biopsy of the prostate for cancer within 12 months of Visit 1.

        Exclusion Criteria:

          -  History of urinary retention or lower urinary tract (bladder) stones 6 months before
             the start of the study

          -  History of bladder outlet obstruction or urethral obstruction due to stricture,
             valves, sclerosis, or tumor.

          -  History of cardiac conditions including angina requiring certain treatment with
             nitrates, heart disease or coronary conditions including myocardial infarction, bypass
             surgery, angioplasty or stent placement for a specified time before starting the
             study.

          -  Certain neurological conditions associated with bladder problems or injuries to the
             brain or spinal cord within a specified time before starting the study.

          -  Nitrate use
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenwood</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Mexico</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2006</study_first_submitted>
  <study_first_submitted_qc>October 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <results_first_submitted>October 17, 2008</results_first_submitted>
  <results_first_submitted_qc>July 7, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2009</results_first_posted>
  <last_update_submitted>August 26, 2009</last_update_submitted>
  <last_update_submitted_qc>August 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Prior to randomization, participants had a 1-4 week Screening/Wash-out Period, followed by a 4 week Placebo Run-In Period. 1813 participants were screened with 755 screen failures, and 1058 participants randomized. The two participants who did not receive study drug were not included in the baseline demographics table.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>placebo tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="P2">
          <title>2.5 mg Tadalafil</title>
          <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="P3">
          <title>5 mg Tadalafil</title>
          <description>5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="P4">
          <title>10 mg Tadalafil</title>
          <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="P5">
          <title>20 mg Tadalafil</title>
          <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="209"/>
                <participants group_id="P3" count="212"/>
                <participants group_id="P4" count="216"/>
                <participants group_id="P5" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Double-Blind Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="208"/>
                <participants group_id="P3" count="212"/>
                <participants group_id="P4" count="216"/>
                <participants group_id="P5" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="182"/>
                <participants group_id="P3" count="182"/>
                <participants group_id="P4" count="175"/>
                <participants group_id="P5" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Didn't Receive Double-Blind Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>placebo tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="B2">
          <title>2.5 mg Tadalafil</title>
          <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="B3">
          <title>5 mg Tadalafil</title>
          <description>5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="B4">
          <title>10 mg Tadalafil</title>
          <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="B5">
          <title>20 mg Tadalafil</title>
          <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="211"/>
            <count group_id="B2" value="208"/>
            <count group_id="B3" value="212"/>
            <count group_id="B4" value="216"/>
            <count group_id="B5" value="209"/>
            <count group_id="B6" value="1056"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.75" spread="7.69"/>
                    <measurement group_id="B2" value="62.03" spread="8.42"/>
                    <measurement group_id="B3" value="61.95" spread="8.17"/>
                    <measurement group_id="B4" value="62.22" spread="7.20"/>
                    <measurement group_id="B5" value="62.55" spread="8.09"/>
                    <measurement group_id="B6" value="62.10" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="211"/>
                    <measurement group_id="B2" value="208"/>
                    <measurement group_id="B3" value="212"/>
                    <measurement group_id="B4" value="216"/>
                    <measurement group_id="B5" value="209"/>
                    <measurement group_id="B6" value="1056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="109"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="108"/>
                    <measurement group_id="B6" value="540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline (Visit 3) Lower Urinary Tract Symptoms (LUTS) Severity</title>
          <description>LUTS Severity was measured with the International Prostate Symptom Score (IPSS), which has a scoring range of 0 to 35. Total scores: 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Moderate (&lt;20 units on a scale: IPSS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="143"/>
                    <measurement group_id="B5" value="141"/>
                    <measurement group_id="B6" value="701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe (&gt;=20 units on a scale: IPSS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="68"/>
                    <measurement group_id="B6" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months to 1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year to 3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="70"/>
                    <measurement group_id="B6" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="107"/>
                    <measurement group_id="B5" value="100"/>
                    <measurement group_id="B6" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erectile Dysfunction</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="144"/>
                    <measurement group_id="B4" value="150"/>
                    <measurement group_id="B5" value="145"/>
                    <measurement group_id="B6" value="716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Collected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Therapy for Benign Prostatic Hyperplasia (BPH)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="158"/>
                    <measurement group_id="B4" value="160"/>
                    <measurement group_id="B5" value="152"/>
                    <measurement group_id="B6" value="762"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="57"/>
                    <measurement group_id="B6" value="294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="179"/>
                    <measurement group_id="B2" value="184"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="186"/>
                    <measurement group_id="B5" value="176"/>
                    <measurement group_id="B6" value="904"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Severity of Erectile Dysfunction (ED)</title>
          <description>Severity was determine only on participants with Erectile Dysfunction using scores on International Index of Erectile Function (IIEF) EF Domain (sum of the scores for Questions 1 through 5 and Question 15) with a range of 0 to 30. Normal EF (â‰¥26), mild ED (17 to 25), moderate ED (11 to 16), and severe ED (1 to 10).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="79"/>
                    <measurement group_id="B6" value="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sexually Active</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="48"/>
                    <measurement group_id="B6" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="174"/>
                    <measurement group_id="B5" value="161"/>
                    <measurement group_id="B6" value="851"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sexually Active and Erectile Dysfunction (ED)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sexually Active with ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="116"/>
                    <measurement group_id="B6" value="581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexually Active without ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="54"/>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Sexually Active with ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Sexually Active without ED</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sexual Activity and/or ED Status is Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary Analysis</title>
        <description>Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Primary analysis was performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet taken by mouth once a day for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>5 mg Tadalafil</title>
            <description>5 mg tadalafil tablet taken by mouth once a day for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS): Primary Analysis</title>
          <description>Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.</description>
          <population>Primary analysis was performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.08" spread="6.36"/>
                    <measurement group_id="O2" value="17.30" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="6.17"/>
                    <measurement group_id="O2" value="-4.92" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is the principal inferential analysis of the primary outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change = Endpoint minus Baseline.</p_value_desc>
            <method>Permutation Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) (Irritative) Subscore</title>
        <description>Measures irritative symptoms over the past 4 weeks of the IPSS. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 1 (few irritative symptoms) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O3">
            <title>5 mg Tadalafil</title>
            <description>5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O5">
            <title>20 mg Tadalafil</title>
            <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) (Irritative) Subscore</title>
          <description>Measures irritative symptoms over the past 4 weeks of the IPSS. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores range from 1 (few irritative symptoms) to 5 (frequent irritative symptoms), thus the 3 questions of the irritative subscore range from 0 to 15.</description>
          <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="208"/>
                <count group_id="O5" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.58" spread="3.09"/>
                    <measurement group_id="O2" value="7.78" spread="2.86"/>
                    <measurement group_id="O3" value="7.65" spread="2.84"/>
                    <measurement group_id="O4" value="7.88" spread="2.67"/>
                    <measurement group_id="O5" value="7.53" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" spread="2.92"/>
                    <measurement group_id="O2" value="-1.62" spread="2.83"/>
                    <measurement group_id="O3" value="-1.91" spread="2.64"/>
                    <measurement group_id="O4" value="-2.04" spread="2.75"/>
                    <measurement group_id="O5" value="-2.05" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.025</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
            <estimate_desc>Mean Difference = 2.5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
            <estimate_desc>Mean Difference = 5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.45</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
            <estimate_desc>Mean Difference = 10 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.58</ci_lower_limit>
            <ci_upper_limit>-0.57</ci_upper_limit>
            <estimate_desc>Mean Difference = 20 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore</title>
        <description>Measures obstructive symptoms over the past 4 weeks of the IPSS. IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 1 (few obstructive symptoms) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.</description>
        <time_frame>12 weeks</time_frame>
        <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O3">
            <title>5 mg Tadalafil</title>
            <description>5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O5">
            <title>20 mg Tadalafil</title>
            <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore</title>
          <description>Measures obstructive symptoms over the past 4 weeks of the IPSS. IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 1 (few obstructive symptoms) to 5 (frequent obstructive symptoms), thus the 4 questions of the obstructive score range from 0 to 20.</description>
          <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="207"/>
                <count group_id="O5" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.51" spread="4.21"/>
                    <measurement group_id="O2" value="9.71" spread="4.16"/>
                    <measurement group_id="O3" value="9.65" spread="4.10"/>
                    <measurement group_id="O4" value="9.88" spread="3.87"/>
                    <measurement group_id="O5" value="9.57" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="4.00"/>
                    <measurement group_id="O2" value="-2.31" spread="3.84"/>
                    <measurement group_id="O3" value="-3.00" spread="3.87"/>
                    <measurement group_id="O4" value="-3.29" spread="4.04"/>
                    <measurement group_id="O5" value="-3.17" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>-0.26</ci_upper_limit>
            <estimate_desc>Mean Difference = 2.5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.40</ci_lower_limit>
            <ci_upper_limit>-0.98</ci_upper_limit>
            <estimate_desc>Mean Difference = 5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.60</ci_lower_limit>
            <ci_upper_limit>-1.18</ci_upper_limit>
            <estimate_desc>Mean Difference = 10 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.59</ci_lower_limit>
            <ci_upper_limit>-1.15</ci_upper_limit>
            <estimate_desc>Mean Difference = 20 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Question 7 (Nocturia)</title>
        <description>Measures nocturia (the need to get up at night to urinate) over the past 4 weeks. Scores range from 1 (few episodes of nocturia) to 5 (frequent episodes of nocturia).</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O3">
            <title>5 mg Tadalafil</title>
            <description>5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O5">
            <title>20 mg Tadalafil</title>
            <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Question 7 (Nocturia)</title>
          <description>Measures nocturia (the need to get up at night to urinate) over the past 4 weeks. Scores range from 1 (few episodes of nocturia) to 5 (frequent episodes of nocturia).</description>
          <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="208"/>
                <count group_id="O5" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="1.10"/>
                    <measurement group_id="O2" value="2.37" spread="1.31"/>
                    <measurement group_id="O3" value="2.36" spread="1.91"/>
                    <measurement group_id="O4" value="2.36" spread="1.15"/>
                    <measurement group_id="O5" value="2.20" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="1.09"/>
                    <measurement group_id="O2" value="-0.43" spread="1.33"/>
                    <measurement group_id="O3" value="-0.49" spread="1.17"/>
                    <measurement group_id="O4" value="-0.43" spread="1.28"/>
                    <measurement group_id="O5" value="-0.54" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.503</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
            <estimate_desc>Mean Difference = 2.5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.206</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
            <estimate_desc>Mean Difference = 5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.452</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.13</ci_upper_limit>
            <estimate_desc>Mean Difference = 10 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
            <estimate_desc>Mean Difference = 20 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index</title>
        <description>Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>5.0 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O5">
            <title>20 mg Tadalafil</title>
            <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index</title>
          <description>Assessment of quality of life (QOL) by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).</description>
          <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="202"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="206"/>
                <count group_id="O5" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="1.19"/>
                    <measurement group_id="O2" value="3.69" spread="1.19"/>
                    <measurement group_id="O3" value="3.54" spread="1.30"/>
                    <measurement group_id="O4" value="3.55" spread="1.23"/>
                    <measurement group_id="O5" value="3.59" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="1.20"/>
                    <measurement group_id="O2" value="-0.86" spread="1.13"/>
                    <measurement group_id="O3" value="-0.92" spread="1.30"/>
                    <measurement group_id="O4" value="-0.98" spread="1.46"/>
                    <measurement group_id="O5" value="-0.97" spread="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.49</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
            <estimate_desc>Mean Difference = 2.5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
            <estimate_desc>Mean Difference = 5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
            <estimate_desc>Mean Difference = 10 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
            <estimate_desc>Mean Difference = 20 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BII)</title>
        <description>Measures the impact that symptoms of BPH has on the patients well being. This questionnaire has 4 questions assessing the level of urinary discomfort and it's impact on the patients. Three questions range from 0 (no impact) to 4 (high impact); one question ranges from 0 (low impact) to 4 (high impact). The BII score ranges from 0 to 16.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O3">
            <title>5 mg Tadalafil</title>
            <description>5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O5">
            <title>20 mg Tadalafil</title>
            <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Benign Prostatic Hyperplasia Impact Index (BII)</title>
          <description>Measures the impact that symptoms of BPH has on the patients well being. This questionnaire has 4 questions assessing the level of urinary discomfort and it's impact on the patients. Three questions range from 0 (no impact) to 4 (high impact); one question ranges from 0 (low impact) to 4 (high impact). The BII score ranges from 0 to 16.</description>
          <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="209"/>
                <count group_id="O5" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" spread="2.95"/>
                    <measurement group_id="O2" value="4.73" spread="2.95"/>
                    <measurement group_id="O3" value="4.66" spread="2.98"/>
                    <measurement group_id="O4" value="4.86" spread="2.98"/>
                    <measurement group_id="O5" value="4.75" spread="2.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="2.52"/>
                    <measurement group_id="O2" value="-0.83" spread="2.66"/>
                    <measurement group_id="O3" value="-1.25" spread="2.75"/>
                    <measurement group_id="O4" value="-1.31" spread="2.79"/>
                    <measurement group_id="O5" value="-1.34" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.583</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.33</ci_upper_limit>
            <estimate_desc>Mean Difference = 2.5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
            <estimate_desc>Mean Difference = 5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
            <estimate_desc>Mean Difference = 10 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
            <estimate_desc>Mean Difference = 20 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Answer &quot;Yes&quot; to the Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ)</title>
        <description>LUTS-GAQ Question asks the participant if the treatment they have been on has improved their uninary symptoms.</description>
        <time_frame>12 weeks</time_frame>
        <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O3">
            <title>5 mg Tadalafil</title>
            <description>5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O5">
            <title>20 mg Tadalafil</title>
            <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Answer &quot;Yes&quot; to the Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ)</title>
          <description>LUTS-GAQ Question asks the participant if the treatment they have been on has improved their uninary symptoms.</description>
          <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="201"/>
                <count group_id="O4" value="200"/>
                <count group_id="O5" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="139"/>
                    <measurement group_id="O4" value="146"/>
                    <measurement group_id="O5" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.133</p_value>
            <p_value_desc>P-values are from Cochran-Mantel-Haenszel test stratified by the randomization strata factors (4 geographic regions, 2 levels of IPSS severity, 2 levels of ED history) as fixed effect, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>P-values are from Cochran-Mantel-Haenszel test stratified by the randomization strata factors (4 geographic regions, 2 levels of IPSS severity, 2 levels of ED history) as fixed effect, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are from Cochran-Mantel-Haenszel test stratified by the randomization strata factors (4 geographic regions, 2 levels of IPSS severity, 2 levels of ED history) as fixed effect, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are from Cochran-Mantel-Haenszel test stratified by the randomization strata factors (4 geographic regions, 2 levels of IPSS severity, 2 levels of ED history) as fixed effect, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in Peak Urinary Flow</title>
        <description>Measures the maximum flow rate of urine (measured in mL/s). This is a continuous parameter with positive numeric values.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O3">
            <title>5 mg Tadalafil</title>
            <description>5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O5">
            <title>20 mg Tadalafil</title>
            <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in Peak Urinary Flow</title>
          <description>Measures the maximum flow rate of urine (measured in mL/s). This is a continuous parameter with positive numeric values.</description>
          <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
          <units>milliliter per second</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="202"/>
                <count group_id="O4" value="201"/>
                <count group_id="O5" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.31" spread="4.85"/>
                    <measurement group_id="O2" value="9.97" spread="4.09"/>
                    <measurement group_id="O3" value="10.37" spread="3.86"/>
                    <measurement group_id="O4" value="9.93" spread="3.77"/>
                    <measurement group_id="O5" value="9.82" spread="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="5.01"/>
                    <measurement group_id="O2" value="1.50" spread="4.56"/>
                    <measurement group_id="O3" value="1.61" spread="3.95"/>
                    <measurement group_id="O4" value="1.69" spread="4.46"/>
                    <measurement group_id="O5" value="2.15" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.735</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
            <estimate_desc>Mean Difference = 2.5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.355</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
            <estimate_desc>Mean Difference = 5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.433</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
            <estimate_desc>Mean Difference = 10 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.089</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.11</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
            <estimate_desc>Mean Difference = 20 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) EF Domain</title>
        <description>Measures erectile function over the past 4 weeks on Questions 1-5 and 15 (6 questions) of the International Index of Erecile Function (IIEF) questionnaire. Scores range from 0 (low/no erectile function) to 5 (high erectile function), thus the 6 questions of the IIEF-EF domain range from 0 to 30.</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from all randomized and sexually active subjects with a history of ED and non-missing data at baseline and at least one postbaseline visit were used for the analysis. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O3">
            <title>5 mg Tadalafil</title>
            <description>5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O5">
            <title>20 mg Tadalafil</title>
            <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Week Endpoint in International Index of Erectile Function (IIEF) EF Domain</title>
          <description>Measures erectile function over the past 4 weeks on Questions 1-5 and 15 (6 questions) of the International Index of Erecile Function (IIEF) questionnaire. Scores range from 0 (low/no erectile function) to 5 (high erectile function), thus the 6 questions of the IIEF-EF domain range from 0 to 30.</description>
          <population>Secondary continuous analyses were performed on an intent-to-treat basis. Data from all randomized and sexually active subjects with a history of ED and non-missing data at baseline and at least one postbaseline visit were used for the analysis. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="113"/>
                <count group_id="O4" value="113"/>
                <count group_id="O5" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.26" spread="7.95"/>
                    <measurement group_id="O2" value="17.42" spread="8.30"/>
                    <measurement group_id="O3" value="15.29" spread="8.13"/>
                    <measurement group_id="O4" value="17.22" spread="8.43"/>
                    <measurement group_id="O5" value="16.28" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" spread="6.32"/>
                    <measurement group_id="O2" value="3.97" spread="7.30"/>
                    <measurement group_id="O3" value="6.56" spread="9.43"/>
                    <measurement group_id="O4" value="6.64" spread="8.29"/>
                    <measurement group_id="O5" value="7.44" spread="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.56</ci_lower_limit>
            <ci_upper_limit>5.17</ci_upper_limit>
            <estimate_desc>Mean Difference = 2.5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>4.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.95</ci_lower_limit>
            <ci_upper_limit>6.54</ci_upper_limit>
            <estimate_desc>Mean Difference = 5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.04</ci_lower_limit>
            <ci_upper_limit>7.62</ci_upper_limit>
            <estimate_desc>Mean Difference = 10 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value for Change from Baseline. Change=Endpoint - Baseline. P-values from ANCOVA model with effect of treatment group, geographic region, and baseline value of analyzed variable as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>6.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.35</ci_lower_limit>
            <ci_upper_limit>7.95</ci_upper_limit>
            <estimate_desc>Mean Difference = 20 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive Analysis</title>
        <description>Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Primary analysis was performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>placebo tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O3">
            <title>5 mg Tadalafil</title>
            <description>5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O4">
            <title>10 mg Tadalafil</title>
            <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
          <group group_id="O5">
            <title>20 mg Tadalafil</title>
            <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in International Prostate Symptom Score (IPSS): Supportive Analysis</title>
          <description>Assesses the severity of BPH-LUTS and the response to therapy. The total score was derived by summing the scores of the responses to the 7 component questions. Scores range from 0 to 35; 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.</description>
          <population>Primary analysis was performed on an intent-to-treat basis. Data from subjects with baseline and at least one postbaseline were used for the analysis. Last observation carried forward.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="205"/>
                <count group_id="O2" value="201"/>
                <count group_id="O3" value="205"/>
                <count group_id="O4" value="207"/>
                <count group_id="O5" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="0.49"/>
                    <measurement group_id="O2" value="-3.81" spread="0.50"/>
                    <measurement group_id="O3" value="-4.83" spread="0.49"/>
                    <measurement group_id="O4" value="-5.13" spread="0.48"/>
                    <measurement group_id="O5" value="-5.17" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is a supportive analysis of the primary outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P-values are from an ANCOVA model with effect of treatment group, geographic region, and IPSS baseline value (at Visit 3) as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.68</ci_lower_limit>
            <ci_upper_limit>-0.48</ci_upper_limit>
            <estimate_desc>Mean Difference = 2.5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a supportive analysis of the primary outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are from an ANCOVA model with effect of treatment group, geographic region, and IPSS baseline value (at Visit 3) as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.69</ci_lower_limit>
            <ci_upper_limit>-1.51</ci_upper_limit>
            <estimate_desc>Mean Difference = 5 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>This is a supportive analysis of the primary outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are from an ANCOVA model with effect of treatment group, geographic region, and IPSS baseline value (at Visit 3) as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.99</ci_lower_limit>
            <ci_upper_limit>-1.81</ci_upper_limit>
            <estimate_desc>Mean Difference = 10 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>This is a supportive analysis of the primary outcome.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are from an ANCOVA model with effect of treatment group, geographic region, and IPSS baseline value (at Visit 3) as a covariate, and were not adjusted for multiple comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.04</ci_lower_limit>
            <ci_upper_limit>-1.84</ci_upper_limit>
            <estimate_desc>Mean Difference = 20 mg Tadalafil minus Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>placebo tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="E2">
          <title>2.5 mg Tadalafil</title>
          <description>2.5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="E3">
          <title>5 mg Tadalafil</title>
          <description>5 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="E4">
          <title>10 mg Tadalafil</title>
          <description>10 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
        <group group_id="E5">
          <title>20 mg Tadalafil</title>
          <description>20 mg tadalafil tablet by mouth once a day for twelve weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6"/>
                <counts group_id="E2" subjects_affected="3"/>
                <counts group_id="E3" subjects_affected="1"/>
                <counts group_id="E4" subjects_affected="2"/>
                <counts group_id="E5" subjects_affected="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Ureteric rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Indwelling catheter management</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Ureteral catheterisation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Ureteral stent insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43"/>
                <counts group_id="E2" subjects_affected="54"/>
                <counts group_id="E3" subjects_affected="65"/>
                <counts group_id="E4" subjects_affected="75"/>
                <counts group_id="E5" subjects_affected="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Left atrial dilatation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Choroidal neovascularisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Eyelid irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Panophthalmitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" events="12" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Duodenogastric reflux</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="212"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="216"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="216"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="216"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Gingival disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="209"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="209"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Vertebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Heart rate abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Podagra</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="216"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="216"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="212"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="209"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="212"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="216"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Nocturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Balanitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Painful erection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Dental operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Sinus operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood pressure fluctuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="212"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>1-800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

